Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Related Research units
Abstract
Bibliographical data
| Original language | English |
|---|---|
| ISSN | 0390-6078 |
| DOIs | |
| Publication status | Published - 01.07.2024 |
| PubMed | 38385280 |
|---|
